EUVIMEDEUVIMED entdecken
Crossref

High-level expression of chromosomally encoded SHV-1 β-lactamase reduces the susceptibility to cefiderocol of clinical isolates of Klebsiella pneumoniae

Rym Charfi, Asmaa Tazi iD, Youssouf Sereme, Céline Plainvert, Hélène Poupet, Alexandra Doloy, Cécile Guyonnet, Philippe Morand, Julien Loubinoux, Claire Poyart, Hedi Mammeri

Journal of Antimicrobial Chemotherapy · 2024

DOI: 10.1093/jac/dkae143 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2024. Verfasst von Rym Charfi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Hôpitaux Universitaires Paris Centre, Site Cochin, Service de Bactériologie, Assistance Publique Hôpitaux de Paris, Paris, France. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, beta-Lactamases, Cefiderocol, Cephalosporins. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 9 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cefiderocol is a siderophore cephalosporin that combines a catechol moiety at position 3 and an R1 side chain at position 7, similar to that of ceftazidime.1 This structure and its unique mechanism of penetration through the TonB-dependent receptors, confer enhanced stability against hydrolysis by many β-lactamases, including ESBLs and carbapenemases.1 As cefiderocol is considered as a last-line therapy against MDR Gram-negative rods, understanding resistance mechanisms is essential for providing solutions to treat infections and to prevent resistance development. Klebsiella pneumoniae harbours a chromosomally encoded bla SHV-1 gene that codes for a penicillinase that exhibits a narrow spectrum of hydrolysis once expressed at basal level but can reduce susceptibility to ceftazidime once overproduced.2 Rice et al. 2 showed that the level of chromosomally encoded SHV-1 β-lactamase production can vary substantially with a single-bp change in promoter sequence. Indeed, a C→A change at position −112 creates an altered −10 box leading to enhanced transcription of the bla SHV-1 gene and subsequently increased MIC of ceftazidime. The aim of our study was to assess the contribution of SHV-1 overproduction to cefiderocol resistance. A collection of five K. pneumoniae isolates that were recovered from clinical samples at the teaching hospital of Cochin (Paris, France), and that exhibited a phenotype of resistance in agreement with SHV-1 overproduction (Table 1), were sequenced and tested for their susceptibility.3 MICs, β-lactamase contents, sequencing metrics, and MLST of the K. pneumoniae clinical isolates and the E. coli recombinant strain aBioSample accession numbers for whole-genome shotgun projects of K. pneumoniae KID1, KID2, LMT, MAC, JPR, CLS and DUM have been deposited at GenBank under accession numbers JBBAIZ000000000, JBBAIY000000000, JBBAJA000000000, JBBAJB000000000, JBBAIX000000000, JBBAIV000000000 and JBBAIW000000000, respectively. bL50 is defined as count of smallest number of sequences whose length sum makes up 50% of the assembly. cMICs were determined using ETEST (bioMérieux; Craponne, France). dMICs were determined using broth microdilution method (Biocentric; Bandol, France). eMICs were performed using broth microdilution method with iron-depleted Mueller–Hinton broth (Biocentric). f K. pneumoniae DUM was a WT clinical isolate used as control. gThe cloned insert was downstream the lacZ promoter. Complete genome sequences of the K. pneumoniae strains were obtained by Illumina sequencing with a NextSeq 500 sequencer at the Mutualized Platform for Microbiology (Institut Pasteur, Paris, France). De novo assembly of the reads was performed using SPAdes 3.15.5, and QUAST 5.2.0 was used to evaluate quality assemblies by computing various metrics (Table 1). The phylogeny of the isolates was inferred from MLST using MLST 2.0, and concatenated alignment of the high-quality SNPs using CSI Phylogeny 1.4 (https://cge.food.dtu.dk) (Table 1). All isolates belonged to different MLST types, except JPR and LMT (Table 1), and they had all more than 150 SNPs of difference, which ruled out clonal relationship (data not shown). Identification of antimicrobial resistance genes using ResFinder 4.1 showed that all isolates only harboured the bla SHV-1 gene, except the K. pneumoniae MAC isolate, which also possessed the bla TEM-1 gene (Table 1) (https://cge.food.dtu.dk). Analysis of the promoter region of the bla SHV-1 gene revealed only an C→A change in the second position of the −10 box in all K. pneumoniae isolates, which was previously demonstrated to be associated with 200-fold greater SHV-1 production.2 Quantitative RT–PCR (RT–qPCR) was carried out,4 using the primers SHV_fwd (5′-TCCCATGATGAGCACCTTTAA-3′) and SHV_rev (5′-TCCTGCTGGCGATAGTGGAT-3′),5 and Rho_RT_F (5′-AACTACGACAAGCCGGAAAA-3′) and Rho_RT_R (5′-ACCGTTACCACGCTCCATAC-3′).6 It confirmed that the bla SHV-1 gene of the resistant isolates KID1, LMT, MAC and JPR was overexpressed compared with that of the WT DUM isolate (Mann–Whitney test, P ≤ 0.2). All the SHV-1-overproducing K. pneumoniae isolates were fully susceptible to cefoxitin and ertapenem (Table 1), which ruled out the contribution of porin deficiency or efflux system overexpression.7 On the other hand, they displayed reduced susceptibility to ceftazidime and cefiderocol, with MICs ranging from 2 to 4 mg/L (Table 1). The isolates remained fully susceptible to cefotaxime whereas the MICs of cefepime were only slightly increased (Table 1). To further demonstrate the contribution of the SHV overproduction to cefiderocol resistance, we cloned the entire bla SHV-1 gene of K. pneumoniae CLS and DUM isolates, including their promoter region, using primers 5′-GTGATCGGCAAACAGCGACG-3′ and 5'-GACCGGCATCTTTCCGATGC-3′, into the pCR-BluntII-TOPO plasmid before transformation in Escherichia coli TOP10.8 It gave rise to the E. coli TOP10 [pSHV-1-prom(+)] and E. coli TOP10 [pSHV-1-prom(-)] recombinant clones, respectively. MICs for the E. coli TOP10 [pSHV-1-prom(+)] strain, which harboured the bla SHV-1 gene with a strong promoter, mirrored those of the SHV-1-overproducing K. pneumoniae isolates, with MICs of ceftazidime and cefiderocol at 2 mg/L. Even if the MIC of cefiderocol did not fall into the resistance range, it was 16-fold increased compared with the WT E. coli TOP10 recipient strain and were at the cut-off limit between susceptibility and resistance (MIC cut-off of >2 mg/L). Moon et al. 9 showed that the production of SHV-5 and SHV-12 ESBLs, which share G238S and E240K replacements compared with SHV-1, conferred resistance to cefiderocol (4–8 mg/L). In our study, we also tested the susceptibility of the K. pneumoniae KID2 isolate that only differed from its K. pneumoniae KID1 parental strain by G238S substitution in SHV-1, thus leading to SHV-2 ESBL. Interestingly, the MICs of cefiderocol for KID1 and KID2 were identical (Table 1), which revealed that the E240K substitution was responsible for the enhanced hydrolytic activity of SHV-5 and SHV-12 against cefiderocol. In conclusion, we demonstrated, using a panel of SHV-1-overproducing K. pneumoniae clinical isolates with genetically well-defined background, that SHV-1 overproduction contributes to reducing the susceptibility to cefiderocol. It reveals that SHV-1 inherently has extended-spectrum activity toward both cefiderocol and ceftazidime, which could be attributable to their identical R1 side chain. This study was supported by internal funding. None to declare.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial Agentsbeta-LactamasesCefiderocolCephalosporinsKlebsiella InfectionsKlebsiella pneumoniaeMicrobial Sensitivity TestsHumansChromosomes, Bacterial

Substanzen

Anti-Bacterial Agentsbeta-LactamasesCefiderocolCephalosporins

Autor:innen und Institutionen

  • Hôpitaux Universitaires Paris Centre, Site Cochin, Service de Bactériologie, Assistance Publique Hôpitaux de Paris, Paris, France.
  • Université de Paris, Institut Cochin, INSERM U1016, CNRS UMR8104, Paris, France.
  • Université Paris Cité, INSERM, CNRS, Institut Necker Enfants Malades, Laboratory of Bacteriology, 75015 Paris, France.

ORCID-Profile: Asmaa Tazi

Zitieren

APA

Charfi, R., Tazi, A., Sereme, Y., Plainvert, C., Poupet, H., Doloy, A., Guyonnet, C., Morand, P., Loubinoux, J., Poyart, C., & Mammeri, H. (2024). High-level expression of chromosomally encoded SHV-1 β-lactamase reduces the susceptibility to cefiderocol of clinical isolates of Klebsiella pneumoniae. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkae143

Vancouver

Charfi R, Tazi A, Sereme Y, Plainvert C, Poupet H, Doloy A, et al. High-level expression of chromosomally encoded SHV-1 β-lactamase reduces the susceptibility to cefiderocol of clinical isolates of Klebsiella pneumoniae. Journal of Antimicrobial Chemotherapy. 2024. doi:10.1093/jac/dkae143

BibTeX
@article{Charfi2024,
  author = {Charfi, Rym and Tazi, Asmaa and Sereme, Youssouf and Plainvert, Céline and Poupet, Hélène and Doloy, Alexandra and Guyonnet, Cécile and Morand, Philippe and Loubinoux, Julien and Poyart, Claire and Mammeri, Hedi},
  title = {High-level expression of chromosomally encoded SHV-1 β-lactamase reduces the susceptibility to cefiderocol of clinical isolates of Klebsiella pneumoniae},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2024},
  doi = {10.1093/jac/dkae143}
}
Kostenlos starten →